Your browser doesn't support javascript.
loading
Developmental vascular malformations in EPAS1 gain-of-function syndrome.
Rosenblum, Jared S; Wang, Herui; Dmitriev, Pauline M; Cappadona, Anthony J; Mastorakos, Panagiotis; Xu, Chen; Jha, Abhishek; Edwards, Nancy; Donahue, Danielle R; Munasinghe, Jeeva; Nazari, Matthew A; Knutsen, Russell H; Rosenblum, Bruce R; Smirniotopoulos, James G; Pappo, Alberto; Spetzler, Robert F; Vortmeyer, Alexander; Gilbert, Mark R; McGavern, Dorian B; Chew, Emily; Kozel, Beth A; Heiss, John D; Zhuang, Zhengping; Pacak, Karel.
Afiliação
  • Rosenblum JS; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Wang H; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Dmitriev PM; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Cappadona AJ; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Mastorakos P; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Xu C; Viral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Jha A; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Edwards N; Section on Medical Neuroendocrinology, Eunice Kennedy Shriver, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
  • Donahue DR; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Munasinghe J; Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Nazari MA; Mouse Imaging Facility, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Knutsen RH; Internal Medicine and Pediatrics, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Rosenblum BR; Laboratory of Vascular and Matrix Genetics, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland, USA.
  • Smirniotopoulos JG; Department of Neurosurgery, Riverview Medical Center, Red Bank, New Jersey, USA.
  • Pappo A; Department of Radiology, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
  • Spetzler RF; National Library of Medicine, Bethesda, Maryland, USA.
  • Vortmeyer A; Oncology Department, Developmental Biology and Solid Tumor Program, St. Jude Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Gilbert MR; Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital, and Medical Center, Phoenix, Arizona, USA.
  • McGavern DB; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Chew E; Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
  • Kozel BA; Viral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
  • Heiss JD; Division of Epidemiology and Clinical Applications, National Eye Institute, NIH, Bethesda, Maryland, USA.
  • Zhuang Z; Laboratory of Vascular and Matrix Genetics, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland, USA.
  • Pacak K; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
JCI Insight ; 6(5)2021 03 08.
Article em En | MEDLINE | ID: mdl-33497361
Mutations in EPAS1, encoding hypoxia-inducible factor-2α (HIF-2α), were previously identified in a syndrome of multiple paragangliomas, somatostatinoma, and polycythemia. HIF-2α, when dimerized with HIF-1ß, acts as an angiogenic transcription factor. Patients referred to the NIH for new, recurrent, and/or metastatic paraganglioma or pheochromocytoma were confirmed for EPAS1 gain-of-function mutation; imaging was evaluated for vascular malformations. We evaluated the Epas1A529V transgenic syndrome mouse model, corresponding to the mutation initially detected in the patients (EPAS1A530V), for vascular malformations via intravital 2-photon microscopy of meningeal vessels, terminal vascular perfusion with Microfil silicate polymer and subsequent intact ex vivo 14T MRI and micro-CT, and histologic sectioning and staining of the brain and identified pathologies. Further, we evaluated retinas from corresponding developmental time points (P7, P14, and P21) and the adult dura via immunofluorescent labeling of vessels and confocal imaging. We identified a spectrum of vascular malformations in all 9 syndromic patients and in all our tested mutant mice. Patient vessels had higher variant allele frequency than adjacent normal tissue. Veins of the murine retina and intracranial dura failed to regress normally at the expected developmental time points. These findings add vascular malformation as a new clinical feature of EPAS1 gain-of-function syndrome.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policitemia / Tumores Neuroendócrinos / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Malformações Vasculares Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: JCI Insight Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policitemia / Tumores Neuroendócrinos / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Malformações Vasculares Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: JCI Insight Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos